Analytical Data
-
基因名
ICF45
- Application
-
别名
THG1L; ICF45; Probable tRNA(His) guanylyltransferase; EC 2.7.7.79; Interphase cytoplasmic foci protein 45; tRNA-histidine guanylyltransferase
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NWX6
-
表达区间
1-269aa
-
氨基酸序列
MAKSKFEYVRDFEADDTCLAHCWVVVRLDGRNFHRFAEKHNFAKPNDSRALQLMTKCAQTVMEELEDIVIAYGQSDEYSFVFKRKTNWFKRRASKFMTHVASQFASSYVFYWRDYFEDQPLLYPPGFDGRVVVYPSNQTLKDYLSWRQADCHINNLYNTVFWALIQQSGLTPVQAQGRLQGTLAADKNEILFSEFNINYNNELPMYRKGTVLIWQKVDEVMTKEIKLPTEMEGKKMAVTRTRTKPVPLHCDIIGDAFWKEHPEILDEDS
-
分子量
55.33 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ICF45, a recombinant protein derived from the Inducible Costimulator (ICOS) pathway, has garnered significant attention in immunology research due to its potential role in modulating immune responses. This pathway is crucial for T-cell activation and proliferation, playing a vital role in the regulation of adaptive immunity. The understanding of ICF45's function has implications for various diseases, including autoimmune disorders, cancers, and infectious diseases. Recent studies suggest that manipulating the ICOS pathway through the use of ICF45 may enhance T-cell responses in cancer immunotherapy or help mitigate excessive immune reactions in autoimmune conditions. To further explore these possibilities, researchers have focused on characterizing the biochemical properties of ICF45, including its interactions with immune cells and its signaling mechanisms. Investigations into the therapeutic applications of ICF45 could lead to novel strategies for enhancing vaccine efficacy or developing personalized treatment approaches in immune-related diseases. With the continuous advancements in recombinant protein technologies, the potential of ICF45 as a therapeutic agent represents a promising frontier in the field of immunotherapy and beyond. Thus, understanding the biology and clinical significance of ICF45 may pave the way for innovative treatments that harness the body's immune system more effectively.
